Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Last trade$16.53
Day change-$0.33 (-1.96%)
Day range$12.59 – $17.11
Volume1,235,355
Market cap$2.43B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.43B
Price / earnings
—
Price / book
6.78×
Price / sales
24.28×
EV / sales
23.79×
EV / EBITDA
-5.12×
Profitability
Earnings per share
-$3.15
Return on assets
-55.38%
Return on equity
-126.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.28×
Current ratio
3.34×
Quick ratio
3.34×
Cash ratio
0.76×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$466M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RCUS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$9M
$41M
$17M
$33M
$26M
$160M
$28M
$26M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$9M
$41M
$17M
$33M
$26M
$160M
$28M
$26M
Selling, general and administrative
$23M
$24M
$29M
$26M
$27M
$29M
$28M
$28M
Research and development
$117M
$113M
$122M
$121M
$141M
$139M
$122M
$101M
Total operating expenses
$140M
$137M
$151M
$147M
$168M
$168M
$150M
$129M
Operating income
-$131M
-$96M
-$134M
-$114M
-$142M
-$8M
-$122M
-$103M
Interest expense
-$3M
-$3M
-$3M
-$2M
-$3M
-$2M
-$1M
-$2M
Income before taxes
-$128M
-$91M
-$128M
-$106M
-$135M
$0
-$112M
-$93M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$1M
Net income
-$128M
-$91M
-$128M
-$106M
-$135M
$0
-$112M
-$94M
Net income attributable to common shareholders
-$128M
-$91M
-$128M
-$106M
-$135M
$0
-$112M
-$94M
EBITDA
-$129M
-$93M
-$132M
-$111M
-$140M
-$6M
-$119M
-$100M
Basic earnings per share
-$1.00
-$0.72
-$1.02
-$0.89
-$1.27
$0.00
-$1.14
-$1.03
Diluted earnings per share
-$1.00
-$0.72
-$1.02
-$0.90
-$1.27
$0.00
-$1.14
-$1.03
Recent news
Company coverage with links to the original publishers.
Summit Therapeutics is expanding its investigational drug ivonescimab beyond non-small cell lung cancer into colorectal and bladder cancer indications. The company has initiated phase III trials for metastatic colorectal cancer and phase II/III studies for advanced bladder cancer. Strategic partnerships with AstraZeneca, GSK, and Arcus Biosciences are evaluating ivonescimab in combination with other cancer therapies, with AstraZeneca committing $2 billion in investment. An FDA decision on ivonescimab for EGFR-mutated NSCLC is expected by November 2026.
Biogen is expected to report Q3 2026 earnings on October 28 with a consensus EPS estimate of $2.04 per share (down 57.6% YoY) and revenues of $2.59 billion (up 2% YoY). With a positive Earnings ESP of +1.81% and Zacks Rank #3 (Hold), the company appears positioned to beat consensus estimates. Biogen has beaten EPS estimates in all four of the last quarters.
Juan C. Jaen, president of Arcus Biosciences, sold 68,569 shares for $2.0 million through a trust under a Rule 10b5-1 trading plan, while maintaining ~1.2 million shares. The sale appears motivated by tax and liquidity management following a 200% stock surge. Arcus has refocused on casdatifan, its HIF-2α kidney cancer drug, after discontinuing a lung cancer program, with pivotal Phase 3 readouts expected by year-end.
The article discusses the global surge in cancer cases, particularly among people under 50, and the efforts of biotech companies to develop new therapies to combat this trend. It highlights recent progress and upcoming studies from several companies in the oncology space.
The global retinoblastoma treatment market is projected to grow from $1.93 billion in 2023 to $2.03 billion in 2024, driven by factors like increased funding, cancer research, and technological advancements. The market is expected to reach $2.56 billion by 2028, growing at a CAGR of 5.9%.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.